Challenges in the management of visceral leishmaniasis.
Sundar
Shyam
S
Kumar
Ashok
A
D000563:Amebicides / Q000627:therapeutic use; D000666:Amphotericin B / Q000627:therapeutic use; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000977:Antiparasitic Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D010303:Paromomycin / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000563:Amebicides; D000977:Antiparasitic Agents; D000981:Antiprotozoal Agents; D007074:Immunoglobulin G; D010767:Phosphorylcholine; C039128:miltefosine; D010303:Paromomycin; D010419:Pentamidine; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate